Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine

• Κύριοι συγγραφείς: Daniel Cowley (Συγγραφέας), Karen Boniface (Συγγραφέας), Nada Bogdanovic-Sakran (Συγγραφέας), Carl D. Kirkwood (Συγγραφέας), Julie E. Bines (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2017-08-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0-5 d ol...